Equator Therapeutics

Market position

Equator positions itself as pursuing a differentiated, first-in-class mechanism for weight regulation — mitochondrial thermogenesis — in contrast to approaches centered on diet and exercise, noting that most people who diet and exercise do not achieve sustained weight loss.

The company describes a singular capacity to directly record the electrical currents that candidate compounds induce in mitochondria, together with high-throughput assays that it says have yielded an unprecedented number of thermogenic compounds, enabling selection for selectivity and safety.

Technology

Equator combines bioelectricity measurement, computational chemistry, and high-throughput interrogation of mitochondrial physiology. Proprietary high-throughput assays have identified a large number of thermogenic compounds, and the company uses direct electrical recording of mitochondrial currents induced by those compounds to select the most selective and safe activators of thermogenesis. The scientific foundations cited by the company include peer-reviewed publications on mitochondrial uncouplers inducing proton leak by activating AAC and UCP1 (Nature, 2022), H+ transport as an integral function of the mitochondrial ADP/ATP carrier (Nature, 2019), and fatty-acid-dependent UCP1 uncoupling in brown fat mitochondria (Cell, 2012).

Go-to-market

As a preclinical therapeutics developer, the company's programs are directed at patients with obesity and metabolic disorders; the company notes that nearly 50% of Americans live with obesity.

Geography

Headquartered in San Francisco, United States, with scientific advisors affiliated with U.S. institutions including UCSF, Yale and Mount Sinai.

History

Equator Therapeutics' work builds on academic research into mitochondrial bioelectricity and uncoupling, reflected in publications from 2012, 2019 and 2022 that the company cites as the foundations of its programs.